In a report issued Monday, Leerink upgraded its rating of InterMune ITMN from Market Perform to Outperform with a target price of $41.
Howard Liang of Leerink anticipates that recent developments in trials done by InterMune should provide the company with plenty of upside. Esbriet particularly is one of the drugs that much of InterMune's success will hinge on, based on Liang's views.
Investors have been extremely bullish on InterMune as it is surging in Monday's session up 14.5 percent to $39.30 at last check.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in